Does Cosentyx Weaken Flu Shot Effectiveness?
Cosentyx (secukinumab) is an IL-17A inhibitor that suppresses parts of the immune system to treat conditions like psoriasis and psoriatic arthritis. It reduces T-cell activity and cytokine production, which can blunt antibody responses to vaccines, including the flu shot. Studies show patients on Cosentyx produce fewer flu-specific antibodies after vaccination compared to healthy people—typically 20-50% lower titers depending on the strain and timing.[1][2]
Evidence from Clinical Studies
In a 2017 trial with psoriasis patients, those on Cosentyx had seroprotection rates (antibody levels >=40 titer) of 45-70% against flu strains post-vaccination, versus 80-95% in placebo groups. Response was better if vaccinated before starting Cosentyx.[3] A 2021 real-world study found similar dampening, but most patients still hit protective thresholds for H1N1 and H3N2 strains.[4] No data shows total failure; protection is partial.
Should You Get the Flu Shot Anyway?
Yes, guidelines from the CDC and Novartis (Cosentyx maker) recommend annual flu shots for patients on biologics like Cosentyx. Live vaccines are avoided due to infection risk, but inactivated flu shots are safe and preferred. Boosters may help overcome reduced response—discuss high-dose or adjuvanted versions with your doctor.[1][5]
Timing and Practical Tips
Vaccinate 2-4 weeks before starting Cosentyx if possible. If already on it, get the shot early in flu season and check antibody levels via blood test if high-risk (e.g., elderly or comorbidities). Avoid live flu vaccine (FluMist).[2][6]
Related Vaccine Concerns with Cosentyx
Cosentyx similarly affects pneumococcal, COVID-19, and shingles vaccines, with 10-30% lower responses. Shingrix (recombinant) works better than live Zostavax. No increased flu shot side effects reported.[3][7]
Doctor Advice and Monitoring
Immune suppression varies by dose, duration, and patient factors. Your rheumatologist or dermatologist can assess via titer tests pre- and post-vaccination. Report flu-like symptoms promptly.[5]
[1]: Novartis Cosentyx Prescribing Information, https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[2]: Bag CK et al., *J Am Acad Dermatol* (2017), "Impact of secukinumab on influenza vaccination response"
[3]: Kivitz A et al., *Ann Rheum Dis* (2017), "Secukinumab immunogenicity and vaccine response"
[4]: Furer V et al., *Vaccine* (2021), "Biologics and influenza vaccine efficacy"
[5]: CDC Guidelines on Immunization for Immunocompromised Adults, https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/immunocompromised.html
[6]: EULAR Recommendations for Vaccination in Rheumatic Diseases (2022)
[7]: CDC ACIP Shingles Vaccine Update (2023)